Akt

  • Compare Akt Products
  • Research Area

Akt Inhibitors (15)

water-soluble

Cat.No. Product Name Information Product Citations Customer Reviews
S1078 MK-2206 2HCl MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
  • Nat Genet, 2014, 46(4):364-70
  • Cancer Cell, 2013, 24(6):766-76
  • Nat Cell Biol, 2013, 15(6):614-24
S1037 Perifosine (KRX-0401) Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt. Phase 3.
  • Cell, 2012, 149(3):656-70
  • Cancer Cell, 2013, 23(6):839-52
  • PLoS Biol, 2011, 9(9):e1001148
S1113 GSK690693 GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
  • Cancer Discov, 2013, 10.1158/2159-8290.CD-13-0520
  • Mol Cell Proteomics, 2012, 11(6):M112.017764
  • Mol Cancer Ther, 2012, 11(7):1510-7
S2808 Ipatasertib (GDC-0068) Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA. Phase 2.
S8019 AZD5363 AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
S2743 PF-04691502 PF-04691502 is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. Phase 2.
  • Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268
  • Cell Signal, 2014, 10.1016/j.cellsig.2014.03.013
  • Apoptosis, 2014, 10.1007/s10495-014-0991-2
S1558 AT7867 AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.
  • Cancer Research, 2012, 72(5):1229-38
  • Cell Signal, 2014, 10.1016/j.cellsig.2014.03.013
  • PLoS One, 2013, 8(2):e57508
S1117 Triciribine Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1 with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
S2635 CCT128930 CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.
S2670 A-674563 A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
Cat.No. Product Name Information Product Citations Customer Reviews
S1556 PHT-427 PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.
  • Blood, 2011, 118(10):2840-8
S3056 Miltefosine Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.
  • Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13
S2310 Honokiol Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.
  • SENSOR ACTUAT B-CHEM, 2012, Jin Akagi
S7127 TIC10 TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
S2732 Triciribine phosphate Triciribine phosphate, the active metabolite of TCN, is a potent Akt inhibitor with IC50 of 130 nM, that inhibits the phosphorylation of Akt in intact cells but not in vitro, more active in cells lacking adenosine kinase. Phase 1/2.
Page:
  • 1
  • 2
All Akt Products
Tags: Akt inhibition | Akt cancer | Akt tumor | Akt activity | Akt activation | Akt inhibitor drugs | Akt phosphorylation | Akt targets | Akt assay | Akt signaling pathway | Akt molecular weight | Akt inhibitor ic50 | Akt inhibitors in clinical trials | Akt inhibitor in vivo | Akt inhibitor review